Hao Desirée, Ritter Mark A, Oliver Tom, Browman George P
Tom Baker Cancer Centre, Alberta Cancer Board and the University of Calgary, Alberta, Canada.
Semin Radiat Oncol. 2006 Jan;16(1):10-9. doi: 10.1016/j.semradonc.2005.08.002.
The addition of concurrent chemotherapy (CT) to standard radiotherapy (RT) for locoregional treatment has been established to improve overall survival in a variety of solid tumors. Among the many CT regimens evaluated in combination with RT in randomized controlled clinical trials and summarized in meta-analyses, platinum-containing regimens have consistently shown a survival benefit across tumor types. Cisplatin and carboplatin have been studied both as single agents and in combination with other cytotoxic drugs, concurrently with RT, but the optimal platinum-based regimen to be combined with RT continues to be explored with further investigation. In this article, the role of platinum-based CT as part of concurrent CT/RT will be discussed using 2 tumor sites in the aerodigestive tract as a paradigm: squamous-cell carcinomas of the head and neck and esophageal carcinomas. For each tumor type, we will review the state of the evidence and comment on the current state of practice and on future directions for clinical research in combined modality CT/RT.
对于局部区域治疗，在标准放疗（RT）基础上加用同步化疗（CT）已被证实可提高多种实体瘤的总生存率。在随机对照临床试验中评估并在荟萃分析中总结的众多与放疗联合的化疗方案中，含铂方案在各种肿瘤类型中均持续显示出生存获益。顺铂和卡铂已作为单一药物以及与其他细胞毒性药物联合，与放疗同步进行了研究，但仍在通过进一步研究探索与放疗联合的最佳铂类方案。在本文中，将以两个上消化道肿瘤部位为范例，讨论铂类化疗作为同步放化疗一部分的作用：头颈部鳞状细胞癌和食管癌。对于每种肿瘤类型，我们将回顾证据状况，并对联合放化疗的当前实践状况以及临床研究的未来方向进行评论。
